About Us

Join us in the discovery and development of next-generation immunotherapies.

Who We Are

Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies. Launched in 2015, we have created and advanced multiple product candidates into clinical trials for autoimmune and inflammatory disease, formed collaborations with world-class partners, and built a robust development pipeline.

Our scientific platform consists of unique protein engineering strategies, including the directed evolution of immune proteins into novel, multi-targeted therapeutics. With such differentiated candidates, we hope to improve outcomes in patients with severe autoimmune and inflammatory diseases.

Our employees (Alpinists) are passionately committed to creating new therapies for patients living with cancer and inflammatory/autoimmune diseases. We believe in innovative thinking, collaboration, flexibility, bias for action, and healthy debate. To foster our team of outstanding scientists and business professionals, we provide a premier work environment with a state-of-the-art lab and office spaces with inspiring views and an open design to facilitate teamwork. Our job listings are available below.

At Alpine, we strive to create a safe, respectful, and inspiring environment in which our team members engage openly and honestly with each other, bringing their work and life experiences to the table.

We seek to lead the next evolution of immunotherapies powered by the diversity of our therapeutic libraries and approaches. We also understand that our success equally relies on the diversity of our team and are committed to building an organization in which everyone has a voice, and we strive for a diversity of backgrounds.


The Alpine Timeline


  • Operations begin


  • $48 million series A financing


  • Completed reverse merger to become publicly listed company (NASDAQ: ALPN)


  • Acazicolcept (ALPN-101) phase 1 initiation


  • $25 million private placement
  • Adaptimmune collaboration and license agreement


  • Acazicolcept phase 1 EULAR presentation


  • AbbVie agreement for up to $865 million, with $60 million upfront
  • $60 million private placement


  • Povetacicept (ALPN-303) ACR presentation and phase 1 healthy volunteer initiation


  • $45 million AbbVie milestone
  • $91 million private placement
  • Horizon Therapeutics agreement for up to $1.52 billion, with $25 million upfront and $15 million equity investment


  • Povetacicept EULAR preclinical and preliminary phase 1 data


  • Appointed Andrew Sandler, MD as Chief Medical Officer
  • Appointed Jörn Drappa, MD, PhD to Board of Directors
  • Completed ~$113M follow on offering in Q3 2022


  • Initiated enrollment of the povetacicept RUBY-3 basket study in autoimmune glomerulonephritis


  • Initiated enrollment of the povetacicept RUBY-4 basket study in autoimmune cytopenias
  • Appointed Christina Yi as Chief Technology Officer.
  • Presented the first clinical data for povetacicept from the RUBY-3 basket study at the American Society of Nephrology in November. 


We are better together

  • We work collaboratively.
  • We challenge and support each other.

We are nimble and move quickly

  • We are action oriented and do what it takes to get the job done.
  • Patients need new therapies urgently.

We are innovative and courageous

  • We take calculated risks to make big advancements in our work.
  • We seek and give honest feedback for growth.

We are operationally excellent

  • We are rigorous, accountable, and reliable.
  • We continuously improve and work efficiently.

Join us in the discovery and development of next-generation immunotherapies.

Current job openings